CD44 and acute myeloid leukemia: Interestingly, experimental data suggest that in AML patients acquiring resistance to the Bcl-2 inhibitor Venetoclax, the minimal residual disease detected in these individuals may be linked to a CXCR4 docking function of CD44 upon CXCL12 engagement [85].